vs
Side-by-side financial comparison of ESAB Corp (ESAB) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $727.8M, roughly 1.4× ESAB Corp). Hologic runs the higher net margin — 17.1% vs 7.5%, a 9.6% gap on every dollar of revenue. On growth, ESAB Corp posted the faster year-over-year revenue change (8.5% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $70.3M). Over the past eight quarters, ESAB Corp's revenue compounded faster (2.8% CAGR vs 1.5%).
ESAB, Elektriska Svetsnings-Aktiebolaget, is an American-Swedish industrial company.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ESAB vs HOLX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $727.8M | $1.0B |
| Net Profit | $54.8M | $179.1M |
| Gross Margin | 37.0% | 56.0% |
| Operating Margin | 14.6% | 22.6% |
| Net Margin | 7.5% | 17.1% |
| Revenue YoY | 8.5% | 2.5% |
| Net Profit YoY | 2.1% | -10.9% |
| EPS (diluted) | $0.90 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $727.8M | $1.0B | ||
| Q3 25 | $715.6M | $1.0B | ||
| Q2 25 | $678.1M | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $670.8M | $1.0B | ||
| Q3 24 | $673.3M | $988.0M | ||
| Q2 24 | $707.1M | $1.0B | ||
| Q1 24 | $689.7M | $1.0B |
| Q4 25 | $54.8M | $179.1M | ||
| Q3 25 | $66.9M | $187.2M | ||
| Q2 25 | $67.4M | $194.9M | ||
| Q1 25 | — | $-17.4M | ||
| Q4 24 | $53.7M | $201.0M | ||
| Q3 24 | $68.2M | $178.6M | ||
| Q2 24 | $82.9M | $194.5M | ||
| Q1 24 | $60.0M | $169.9M |
| Q4 25 | 37.0% | 56.0% | ||
| Q3 25 | 37.2% | 55.6% | ||
| Q2 25 | 37.6% | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | 38.5% | 56.8% | ||
| Q3 24 | 37.7% | 56.4% | ||
| Q2 24 | 38.2% | 55.4% | ||
| Q1 24 | 37.0% | 53.3% |
| Q4 25 | 14.6% | 22.6% | ||
| Q3 25 | 15.2% | 22.6% | ||
| Q2 25 | 16.2% | 24.9% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | 16.6% | 22.5% | ||
| Q3 24 | 15.7% | 23.3% | ||
| Q2 24 | 16.9% | 24.1% | ||
| Q1 24 | 16.0% | 20.7% |
| Q4 25 | 7.5% | 17.1% | ||
| Q3 25 | 9.3% | 17.8% | ||
| Q2 25 | 9.9% | 19.0% | ||
| Q1 25 | — | -1.7% | ||
| Q4 24 | 8.0% | 19.7% | ||
| Q3 24 | 10.1% | 18.1% | ||
| Q2 24 | 11.7% | 19.2% | ||
| Q1 24 | 8.7% | 16.7% |
| Q4 25 | $0.90 | $0.79 | ||
| Q3 25 | $1.09 | $0.84 | ||
| Q2 25 | $1.10 | $0.86 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | $0.87 | $0.87 | ||
| Q3 24 | $1.11 | $0.75 | ||
| Q2 24 | $1.35 | $0.82 | ||
| Q1 24 | $0.98 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.2M | $2.4B |
| Total DebtLower is stronger | $1.3B | $2.5B |
| Stockholders' EquityBook value | $2.1B | $5.2B |
| Total Assets | $4.9B | $9.2B |
| Debt / EquityLower = less leverage | 0.63× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.2M | $2.4B | ||
| Q3 25 | $258.2M | $2.2B | ||
| Q2 25 | $291.3M | $1.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $249.4M | $2.0B | ||
| Q3 24 | $253.7M | $2.3B | ||
| Q2 24 | $228.5M | $2.4B | ||
| Q1 24 | $76.5M | $2.2B |
| Q4 25 | $1.3B | $2.5B | ||
| Q3 25 | $1.1B | $2.5B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $1.1B | $2.5B | ||
| Q3 24 | $1.1B | $2.5B | ||
| Q2 24 | $1.1B | $2.5B | ||
| Q1 24 | $992.8M | $2.6B |
| Q4 25 | $2.1B | $5.2B | ||
| Q3 25 | $2.1B | $5.0B | ||
| Q2 25 | $1.9B | $4.8B | ||
| Q1 25 | — | $4.6B | ||
| Q4 24 | $1.8B | $4.8B | ||
| Q3 24 | $1.8B | $5.1B | ||
| Q2 24 | $1.7B | $5.0B | ||
| Q1 24 | $1.6B | $4.8B |
| Q4 25 | $4.9B | $9.2B | ||
| Q3 25 | $4.4B | $9.0B | ||
| Q2 25 | $4.2B | $8.8B | ||
| Q1 25 | — | $8.5B | ||
| Q4 24 | $4.0B | $8.7B | ||
| Q3 24 | $4.1B | $9.2B | ||
| Q2 24 | $4.0B | $8.9B | ||
| Q1 24 | $3.8B | $8.7B |
| Q4 25 | 0.63× | 0.48× | ||
| Q3 25 | 0.51× | 0.50× | ||
| Q2 25 | 0.55× | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 0.60× | 0.53× | ||
| Q3 24 | 0.59× | 0.49× | ||
| Q2 24 | 0.63× | 0.51× | ||
| Q1 24 | 0.61× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $81.5M | $229.9M |
| Free Cash FlowOCF − Capex | $70.3M | $215.2M |
| FCF MarginFCF / Revenue | 9.7% | 20.5% |
| Capex IntensityCapex / Revenue | 1.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.49× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $238.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.5M | $229.9M | ||
| Q3 25 | $46.6M | $355.1M | ||
| Q2 25 | $35.4M | $343.3M | ||
| Q1 25 | — | $169.4M | ||
| Q4 24 | $126.9M | $189.3M | ||
| Q3 24 | $101.0M | $367.0M | ||
| Q2 24 | $83.0M | $405.8M | ||
| Q1 24 | $44.5M | $292.4M |
| Q4 25 | $70.3M | $215.2M | ||
| Q3 25 | $37.4M | $341.4M | ||
| Q2 25 | $28.1M | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | $102.2M | $172.5M | ||
| Q3 24 | $90.4M | $350.6M | ||
| Q2 24 | $74.0M | $385.3M | ||
| Q1 24 | $37.1M | $279.6M |
| Q4 25 | 9.7% | 20.5% | ||
| Q3 25 | 5.2% | 32.5% | ||
| Q2 25 | 4.1% | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | 15.2% | 16.9% | ||
| Q3 24 | 13.4% | 35.5% | ||
| Q2 24 | 10.5% | 38.1% | ||
| Q1 24 | 5.4% | 27.5% |
| Q4 25 | 1.5% | 1.4% | ||
| Q3 25 | 1.3% | 1.3% | ||
| Q2 25 | 1.1% | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 3.7% | 1.6% | ||
| Q3 24 | 1.6% | 1.7% | ||
| Q2 24 | 1.3% | 2.0% | ||
| Q1 24 | 1.1% | 1.3% |
| Q4 25 | 1.49× | 1.28× | ||
| Q3 25 | 0.70× | 1.90× | ||
| Q2 25 | 0.53× | 1.76× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.36× | 0.94× | ||
| Q3 24 | 1.48× | 2.05× | ||
| Q2 24 | 1.00× | 2.09× | ||
| Q1 24 | 0.74× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
